References
- Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 14: 340: 115–26.
- Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 17: 104: 365–72.
- Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein lib/Ilia blockade in coronary artery disease. J Am Coll Cardiol 2000; 35: 1103–15.
- George J, Ben-Shmuel S, Roth A et al. L-Arginine attenuates lymphocyte activation and anti-oxidized LDL antibody levels in patients undergoing angioplasty. Atherosclerosis 2004; 174: 323–7.
- Lincoff AM, Kereiakes DJ, Marcelli MA et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001; 104: 163–7.
- Topol EJ, Moliterno DJ, Herrmann HC et al. Comparison of two platelet glycoprotein IIB/IIIA inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1937–9.